Keywords: Biogen Idec, Swedish Orphan Biovitrum, Hemophilia B, rFIXFc, rFVIIIFc, USA, FDA

Biogen Idec files for US approval of hemophilia B treatment

Article | 07 January 2013

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) on Friday announced it has submitted a Biologics License Application (BLA) to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in